Advertisement
Canada markets open in 7 hours 33 minutes

  • S&P/TSX

    21,740.20
    -159.79 (-0.73%)
     

  • S&P 500

    5,061.82
    -61.59 (-1.20%)
     

  • DOW

    37,735.11
    -248.13 (-0.65%)
     

  • CAD/USD

    0.7250
    -0.0003 (-0.04%)
     

  • CRUDE OIL

    86.05
    +0.64 (+0.75%)
     

  • Bitcoin CAD

    86,395.18
    -3,851.98 (-4.27%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,402.30
    +19.30 (+0.81%)
     

  • RUSSELL 2000

    1,975.71
    -27.47 (-1.37%)
     

  • 10-Yr Bond

    4.6280
    -4.4990 (-49.29%)
     

  • NASDAQ futures

    17,868.25
    -8.00 (-0.04%)
     

  • VOLATILITY

    19.23
    +1.92 (+11.09%)
     

  • FTSE

    7,965.53
    -30.05 (-0.38%)
     

  • NIKKEI 225

    38,523.21
    -709.59 (-1.81%)
     

  • CAD/EUR

    0.6825
    +0.0001 (+0.01%)
     
MARKETS LIVE BLOG:

STOCKS SLIP WITH MIDEAST TENSIONS, EARNINGS IN PLAY

Oil pares losses as traders anticipate Israel's response to Iranian attack

Today's Research Reports on Aptose Biosciences, ProMIS Neurosciences, Emblem and BELLUS Health

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / December 18, 2018 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://marketedgereport.com and get exclusive access to our numerous research reports and market updates.

The Market Edge Initiates Coverage on:

Aptose Biosciences Inc.
https://marketedgereport.com/report/APS.TO/

ProMIS Neurosciences, Inc.
https://marketedgereport.com/report/PMN.TO/

Emblem Corp.
https://marketedgereport.com/report/EMC.V/

BELLUS Health Inc.
https://marketedgereport.com/report/BLU.TO/

ADVERTISEMENT

Aptose Biosciences' stock moved 2.66% lower Monday, to close the day at $2.93. The stock recorded a trading volume of 48,720 shares, which was above its three months average volume of 41,770 shares. In the last year, Aptose Biosciences' shares have traded in a range of 2.18 - 5.97. The share price has gained 34.4% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $2.93 is lower than its 200-day moving average of $3.73. Shares of Aptose Biosciences have gained approximately 5.4 percent year-to-date.

Access The Market Edge's Aptose Biosciences Inc. Research Report:
https://marketedgereport.com/report/APS.TO/

On Monday, shares of ProMIS Neurosciences recorded a trading volume of 44,680 shares, which was below the three months average volume of 188,835 shares. The stock ended the day 4.65% higher at $0.225. The share price has fallen 69.18% from its 52 week high with a 52 week trading range of 0.19 - 0.73. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.243 is lower than its 200-day moving average of $0.309. Shares of ProMIS Neurosciences have gained approximately 15 percent year-to-date.

Access The Market Edge's ProMIS Neurosciences, Inc. Research Report:
https://marketedgereport.com/report/PMN.TO/

Emblem's stock had no change Monday, to close the day at $1.00. The stock recorded a trading volume of 791,883 shares, which was above its three months average volume of 694,159 shares. In the last year, Emblem's shares have traded in a range of 0.83 - 2.76. The share price has gained 20.48% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $1.19 is lower than its 200-day moving average of $1.36. Shares of Emblem have fallen approximately 56.14 percent year-to-date.

Access The Market Edge's Emblem Corp. Research Report:
https://marketedgereport.com/report/EMC.V/

On Monday, shares of BELLUS Health recorded a trading volume of 1,632,618 shares, which was above the three months average volume of 235,942 shares. The stock ended the day 12.17% higher at $1.29. The share price has fallen 0.77% from its 52 week high with a 52 week trading range of 0.33 - 1.30. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.97 is greater than its 200-day moving average of $0.82. Shares of BELLUS Health have gained approximately 248.65 percent year-to-date.

Access The Market Edge's BELLUS Health Inc. Research Report:
https://marketedgereport.com/report/BLU.TO/

Our Actionable Research on Aptose Biosciences Inc. (TSX:APS.TO), ProMIS Neurosciences, Inc. (TSX:PMN.TO), Emblem Corp. (TSXV:EMC.V) and BELLUS Health Inc. (TSX:BLU.TO) can be downloaded free of charge at The Market Edge.

The Market Edge

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

The Market Edge has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of MarketEdgeReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketEdgeReport.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.marketedgereport.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

The Market Edge, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@marketedgereport.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: MarketEdgeReport